FDA ad­dress­es ex­pand­ed use of da­ta mon­i­tor­ing com­mit­tees in draft guid­ance

The FDA laid out con­sid­er­a­tions for how spon­sors should lever­age com­mit­tees to help an­a­lyze clin­i­cal tri­al da­ta in draft guid­ance

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.